Sanofi terminates SAR448272 program
Nurix Therapeutics said Sanofi notified the company of its decision to terminate the SAR448272 program.
Related stories
Jack Henry Q1 revenue totals USD 701.547 million
M impact | EQUITY | Nov 03, 2026, 09:51 PM UTC
GXO Logistics Q3 earnings snapshot
M impact | EQUITY | Nov 03, 2026, 09:50 PM UTC
Skyworks Solutions Reports Fiscal Q4 Earnings and Revenue Declines, Sets Q1 Guidance
Skyworks Solutions reported declines in fiscal Q4 adjusted earnings and revenue and set guidance for Q1.
M impact | EQUITY | Nov 03, 2026, 09:50 PM UTC
Mosaic Posts Q3 Revenue of $3.1B vs. FactSet Estimate of $3.05B
M impact | EQUITY | Nov 03, 2026, 09:50 PM UTC
Kadant Q3 Revenue Beats Estimates as Acquisitions Boost Results
M impact | EQUITY | Nov 03, 2026, 09:49 PM UTC
AMD Q3 Operating Income More Than Doubles to $2.83 Billion
AMD said Q3 revenue rose 45% year over year to $13.38 billion.
M impact | EQUITY | Nov 03, 2026, 09:49 PM UTC